← back to search

C. Gregory Elliott

Intermountain Healthcare ·
Area of research
Pulmonary and Respiratory Medicine · Internal Medicine
Research interest
Research interests include Pulmonary Hypertension Research and Treatments, Venous Thromboembolism Diagnosis and Management, Atrial Fibrillation Management and Outcomes, and Chronic Obstructive Pulmonary Disease (COPD) Research.
h-index
73
citations
24,456
works
303
NIH funding
primary concept
email

Recent publications

Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
Genetics in Medicine 2023cited by 70position: middledoi
Long-term Survival and Quality of Life
CHEST Pulmonary 2023cited by 10position: middledoi
Real‐world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real‐world Evidence Working Group
Pulmonary Circulation 2023cited by 4position: lastdoi
Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
American Journal of Respiratory and Critical Care Medicine 2021cited by 218position: middledoi
Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial
Blood Advances 2021cited by 156position: lastdoi
Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry
CHEST Journal 2021cited by 73position: middledoi
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension
CHEST Journal 2020cited by 308position: middledoi
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Journal of the American College of Cardiology 2020cited by 63position: middledoi
United States Pulmonary Hypertension Scientific Registry
CHEST Journal 2020cited by 63position: middledoi
Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study
The American Journal of Emergency Medicine 2020cited by 33position: lastdoi
Predicting Survival in Patients With Pulmonary Arterial Hypertension
CHEST Journal 2019cited by 624position: middledoi
Therapy for Pulmonary Arterial Hypertension in Adults
CHEST Journal 2019cited by 297position: middledoi
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
Pulmonary Circulation 2019cited by 10position: firstdoi
Genetics and genomics of pulmonary arterial hypertension
European Respiratory Journal 2018cited by 461position: middledoi
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
New England Journal of Medicine 2018cited by 245position: middledoi
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
The Lancet Respiratory Medicine 2018cited by 210position: middledoi
Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension
American Journal of Respiratory and Critical Care Medicine 2018cited by 109position: middledoi
Management of Low-Risk Pulmonary Embolism Patients Without Hospitalization
CHEST Journal 2018cited by 79position: lastdoi
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension
CHEST Journal 2018cited by 58position: middledoi
Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism
CHEST Journal 2017cited by 10position: lastdoi
EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension
CHEST Journal 2016cited by 77position: lastdoi
Five-Year Outcomes of Patients Enrolled in the REVEAL Registry
CHEST Journal 2015cited by 517position: middledoi
VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock
CHEST Journal 2015cited by 280position: middledoi
Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects
Human Mutation 2015cited by 227position: middledoi
Validation of two predictive models for survival in pulmonary arterial hypertension
European Respiratory Journal 2015cited by 100position: middledoi
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome
Clinical and Applied Thrombosis/Hemostasis 2015cited by 98position: lastdoi
Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults
CHEST Journal 2014cited by 257position: middledoi
Genetics of pulmonary hypertension
Current Opinion in Cardiology 2014cited by 44position: lastdoi
Assessment of the Safety and Efficiency of Using an Age-Adjusted D-dimer Threshold to Exclude Suspected Pulmonary Embolism
CHEST Journal 2014cited by 36position: lastdoi
Genetics and Genomics of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology 2013cited by 620position: middledoi

Grants

Electrochemically Active Polymers - Designing Compositional Structures and Electronic Properties
NSF0139637$432,0002002–2006PIRePORTER
ITR/SY(MPS): Molecular-Based Optical Detection of Weak Magnetic Fields
NSF0113112$498,5982001–2005PIRePORTER
Electroactive Polymers-Applications to Analysis, New Materials and Catalysis
NSF9714081$408,8601998–2001PIRePORTER
Electroactive Polymers--Application to Analysis, Catalysis and Fundamental Studies
NSF9311694$339,8501993–1997PIRePORTER
Postdoctoral Research Fellowship in Plant Biology
NSF9008307$64,8001990–1993PIRePORTER
Linked Donor/Acceptor/Photosensitizer Systems
NSF8821752$182,0121989–1992PIRePORTER
Electroactive Polymers
NSF8813707$100,0001988–1991PIRePORTER
Chemical Reactions On and With Surfaces
NSF8712457$173,6001987–1990PIRePORTER
Linked Donor/Acceptor/Photosensitizer Systems
NSF8516904$190,2381986–1989PIRePORTER
Linked Donor-Acceptor Photosensitizer Systems (Chemistry)
NSF8214299$132,0001983–1986PIRePORTER

Frequent collaborators

Scott M. Stevens · Intermountain Healthcare9 papers (2012–2021)Scott C. Woller · New York University9 papers (2012–2021)James F. Lloyd · Intermountain Healthcare8 papers (2012–2021)Raymond L. Benza · Sentara Norfolk General Hospital8 papers (2015–2023) · 7 papers (2012–2021)Harrison W. Farber · Tufts University7 papers (2012–2020)David B. Badesch · German Center for Lung Research6 papers (2014–2019)Adaani Frost · Houston Methodist6 papers (2012–2019)R. Scott Evans · University of Utah5 papers (2012–2017) · 5 papers (2012–2019)Joseph Bledsoe · National Heart Lung and Blood Institute5 papers (2012–2020)Wendy K. Chung · Oregon Health & Science University5 papers (2013–2019) · 4 papers (2012–2020)D. Hunter Best · University of Utah4 papers (2013–2016)Erika B. Rosenzweig · New York Medical College4 papers (2013–2021)Eric D. Austin · Regeneron (United States)4 papers (2013–2019)James E. Loyd · National Heart Lung and Blood Institute3 papers (2013–2018)Richard N. Channick · Loyola University Medical Center3 papers (2013–2023)Robert P. Frantz · University of Florida3 papers (2018–2021)Marc Humbert · Médecins Sans Frontières3 papers (2013–2015)